🎁 Black Friday: up to 50% off of annual plans
Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
41.25
-5.40 (-11.58%)
At close: Nov 20, 2026

Pet Pharm Biotech Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
266.86222.03130.7117.8775.74
Revenue Growth
40.06%69.88%10.89%55.62%-
Cost of Revenue
128.52105.5960.7453.2739.88
Gross Profit
138.34116.4469.9664.5935.86
Selling, General & Admin
102.6491.6949.7444.1631.71
Research & Development
11.91012.1414.057.79
Operating Expenses
114.56101.761.8557.0140.7
Operating Income
23.7814.748.117.59-4.84
Interest Expense
-1.44-0.89-0.18-0.18-0.2
Interest & Investment Income
5.866.794.11.670.45
Currency Exchange Gain (Loss)
0.040.040.230.060.12
Other Non Operating Income (Expenses)
18.313.520.150.010.96
EBT Excluding Unusual Items
46.5524.212.429.15-3.5
Gain (Loss) on Sale of Assets
-----0.21
Asset Writedown
0.07----0.1
Other Unusual Items
-0.03-0.03---
Pretax Income
46.624.1712.429.15-3.81
Income Tax Expense
-0.72-0.72-2.09--
Earnings From Continuing Operations
47.3224.914.519.15-3.81
Minority Interest in Earnings
0.120.09---
Net Income
47.4524.9914.519.15-3.81
Net Income to Common
47.4524.9914.519.15-3.81
Net Income Growth
114.51%72.25%58.54%--
Shares Outstanding (Basic)
5955413025
Shares Outstanding (Diluted)
5955413025
Shares Change
14.85%32.26%37.19%19.84%-
EPS (Basic)
0.810.460.350.30-0.15
EPS (Diluted)
0.810.450.350.30-0.16
EPS Growth
87.02%28.44%17.07%--

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
137.414.79-159.518.08-27.87
Free Cash Flow Per Share
2.350.09-3.850.27-1.11
Dividend Per Share
0.2460.2460.0890.194-
Dividend Growth
177.68%177.68%-54.37%--
Gross Margin
51.84%52.44%53.53%54.80%47.34%
Operating Margin
8.91%6.64%6.21%6.44%-6.39%
Profit Margin
17.78%11.25%11.10%7.76%-5.03%
Free Cash Flow Margin
51.49%2.16%-122.05%6.85%-36.80%
EBITDA
59.5738.1919.4518.755.89
EBITDA Margin
22.32%17.20%14.88%15.91%7.78%
D&A For EBITDA
35.7923.4511.3411.1710.73
EBIT
23.7814.748.117.59-4.84
EBIT Margin
8.91%6.64%6.21%6.44%-6.39%